Oncology Pharma Inc
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated … Read more
Oncology Pharma Inc (ONPH) - Total Assets
Latest total assets as of December 2022: $2.14 Million USD
Based on the latest financial reports, Oncology Pharma Inc (ONPH) holds total assets worth $2.14 Million USD as of December 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncology Pharma Inc - Total Assets Trend (1996–2022)
This chart illustrates how Oncology Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncology Pharma Inc - Asset Composition Analysis
Current Asset Composition (March 2022)
Oncology Pharma Inc's total assets of $2.14 Million consist of 0.2% current assets and 99.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2022)
This chart illustrates how Oncology Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncology Pharma Inc's current assets represent 0.2% of total assets in 2022, a decrease from 91.5% in 1996.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2022, down from 83.1% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Oncology Pharma Inc Competitors by Total Assets
Key competitors of Oncology Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncology Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oncology Pharma Inc generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Oncology Pharma Inc generates $ 93.68 in net profit.
Oncology Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.25 | 2.53 |
| Quick Ratio | 0.00 | 0.02 | 2.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.04 Million | $ -489.82K | $ 2.06 Million |
Oncology Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Oncology Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 510.7% |
| Total Assets | $2.12 Million |
| Market Capitalization | $0.93 USD |
Valuation Analysis
Below Book Valuation: The market values Oncology Pharma Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oncology Pharma Inc's assets grew by 510.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oncology Pharma Inc (1996–2022)
The table below shows the annual total assets of Oncology Pharma Inc from 1996 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-03-31 | $2.12 Million | +510.71% |
| 2021-03-31 | $347.55K | +50.55% |
| 2020-03-31 | $230.85K | +21.16% |
| 2019-03-31 | $190.54K | -4.05% |
| 2013-03-31 | $198.59K | -24.25% |
| 2011-03-31 | $262.16K | +446.17% |
| 2004-03-31 | $48.00K | -97.26% |
| 2003-03-31 | $1.75 Million | -51.51% |
| 2002-03-31 | $3.61 Million | -29.76% |
| 2001-03-31 | $5.14 Million | -23.29% |
| 2000-03-31 | $6.70 Million | +598.69% |
| 1998-03-31 | $959.25K | -44.10% |
| 1997-03-31 | $1.72 Million | -45.27% |
| 1996-03-31 | $3.14 Million | -- |